Thanks! You've successfully subscribed to the BONEZONE®/OMTEC® Monthly eNewsletter!

Please take a moment to tell us more about yourself and help us keep unwanted emails out of your inbox.

Choose one or more mailing lists:
BONEZONE/OMTEC Monthly eNewsletter
OMTEC Conference Updates
Advertising/Sponsorship Opportunities
Exhibiting Opportunities
* Indicates a required field.

The Global Orthopaedic Supplier Market

By the end of 2Q12, Greatbatch announced plans to open a manufacturing facility in Ft. Wayne, Indiana to consolidate its orthopaedic operations there. Meanwhile, Symmetry noted a slight uptick in instrument sales and stable results for implants as order activity rose above usual year-over-year levels. Further, Symmetry, while seeking transparency on inventory practices from its customers, mentioned that it was encouraged by what was happening on those fronts.

At OMTEC 2012, Brian Moore, former Symmetry CEO, confirmed that such factors as OEM inventory handling will continue to be far more important to growth for the supplier companies than will orthopaedic procedure volumes, though the supplier base will naturally continue to ebb and flow in reaction to the OEMs’ strategies.

An additional challenge is presented in FDA’s requirement that, as of October 2012, contract manufacturers must register and list the products that they make on the FDA Unified Registration and Listing or FURLS database. Such action could accelerate supplier rationalization as OEMs are facing more strict quality and regulatory scrutiny, themselves.

Moving forward, OEMs will continue to consolidate their supply chains, and suppliers will continue to merge and acquire to meet the OEMs’ needs. A number of such transactions occurred in 2011 and 2012 to date (3Q12), as illustrated in Exhibit 2.

Exhibit 2: Supplier Merger & Acquisition Activity: 2011 to 3Q12 

Qtr/Yr Close Acquired Acquired by Transaction Value ($MM) Sales ($MM) Sales Multiple
4Q12 In'Tech Medical TCR/Arkea Capital Cash n/a $38.0  n/a 
3Q12 Teleflex OEM orthopaedic business Tecomet Cash $45.2 $36.0  1.26
2Q12 Kensey Nash DSM Cash for stock $360.0 $25.6  14.06
2Q12 ETI MRPC Terms not disclosed  n/a  n/a  n/a 
1Q12 Sandvik Medical Altor (Orchid Orthopedic) Terms not disclosed  n/a  $90.0  n/a 
1Q12 Remmele Engineering RTI Intl Metals Cash and debt $182.5 n/a  n/a 
4Q11 ATS-Sferic Marle International Terms not disclosed  n/a  n/a  n/a 
3Q11 Hower Tool Haven Manufacturing Terms not disclosed  n/a  n/a  n/a 
3Q11 Boston Endo-Surgical Technologies Precision Engineered Products Terms not disclosed  n/a  n/a  n/a 
3Q11 Geisert Square Valtronic Terms not disclosed  n/a  n/a  n/a 
3Q11 Olsen Medical Symmetry Medical Cash $11.0 n/a  n/a 
3Q11 Structure Medical Squadron Capital Terms not disclosed  n/a  n/a  n/a 
3Q11 Hansa Medical Squadron Capital Terms not disclosed  n/a  n/a  n/a 
3Q11 Kemac Technology Tecomet Terms not disclosed  n/a  n/a  n/a 
3Q11 Solidscape Stratysys Terms not disclosed $38.0 $13.4  2.84
2Q11 Orchid Orthopedic Solutions Altor Terms not disclosed  n/a  n/a  n/a 
2Q11 Marcam Engineering Materialise Terms not disclosed  n/a  n/a  n/a 
1Q11 Sierra Manufacturing United Site Services Terms not disclosed  n/a  n/a  n/a 
1Q11 Concordia Medical Biomedical Structures Terms not disclosed  n/a  n/a  n/a 
1Q11 Nerites Kensey Nash Cash $20.0 n/a  n/a 
1Q11 Orliman Riverside (private equity) Terms not disclosed  n/a  $19.2  n/a 

Despite a slowing to mid-single-digit growth, the orthopaedic market should remain healthy due to solid demographics: an aging population, a more active and more demanding patient, increased reach into BRIC countries, etc.

To keep pace with the OEMs needs, suppliers may find success in offering services other than contract manufacturing, such as Ceram’s regulatory assistance package, Squadron’s customer financing services, etc., to device manufacturers that find themselves more thinly-spread. OEMs and suppliers will work together to build new paths to growth in orthopaedics.